Shreis Scalene Clinicals Inc.

Shréis Scalene Clinical Inc. (Shréis) has been established for the sole purpose of conducting Clinical trials,  in-licensing technologies in the clinical stage of development, from Shreis Scalene Sciences, the parent R&D company. Shréis Scalene Clinicals Inc. (Shréis) was founded by Prof. Meena Augustus PhD, President, CEO & CSO, and Rayol J Augustus Ph.D., Co-Founder & COO.  The primary purpose is to conduct US-FDA mandated Clinical Trials for the CYTOTRON®;  and introduce another cutting edge technology, termed  Focused Resonance Nano-permeabilization (FORN®), enabled by CELLFORN® - a device for the enhancement of drug delivery for patients on chemotherapy.  Shréis will accomplish these objectives in partnerships with leading academic / cancer treatment centers / big pharma,  to improve clinical benefit for adult and pediatric  cancer patients, and improve the performance profiles of drugs in cancer and pain relief drug pipelines. Shréis has exclusive marketing rights for the Americas, Mexico, and the Caribbean, with the ability to sell devices in the UK and Europe.

The patent protected CYTOTRON Device and technology (US9,162,076 B2/ with European & Chinese patents issued),  has US-FDA Breakthrough Designation for the treatment of Breast, Pancreas and Liver Cancers, based on preliminary data submitted on all solid tumors, including adult Glioblastomas and treatment refractory, pediatric Brainstem Gliomas.  FORN® is a novel, clinically validated and patent protected (WO 2010-106544 A1), state-of-the-art drug delivery device & technology, used for the treatment of cancer in conjunction with chemotherapy. Shreis is seeking to establish large pharma / equity partnerships to collaborate and conduct clinical trials, that will lead to global commercialization of the CYTOTRON® & CELLFORN® technologies, by specifically improving clinical outcomes, and enhancing the effect of the drugs used in Cancer chemotherapy, and improving prevailing toxicity profiles, respectively.